AIPM welcomes new members: Alexion, Ferring Pharmaceuticals and Gilead Sciences join the Association

December 13, 2013, Moscow - The Association of International Pharmaceutical Manufacturers (AIPM) announces extension of the member list. On December 4, 2013 during the General Meeting of AIPM members it was decided that international pharmaceutical companies Alexion, Ferring Pharmaceuticals and Gilead Sciences join the Association.

“Development of innovations in the Russian pharmaceutical industry is the right step towards improving drug provision in the country. AIPM supports this policy consistently following its mission to increase the quality of medical care and expand the range of modern medications for the benefit of the Russian people. The General Meeting of the Association members made a positive decision on joining of three companies at once that develop unique therapeutic solutions. I am convinced that the international expertise of the new AIPM members will be extremely useful for addressing the challenges that the Russian healthcare faces,” said Vladimir Shipkov, AIPM Executive Director.

“Patients that suffer from orphan diseases are the ones who often experience difficulties with access to modern medications that could significantly improve their condition. AIPM initiatives aimed particularly at solving the key problems with drug provision for this category of patients are crucial. We are convinced that Alexion as an AIPM member will be able to contribute to improving the quality of life and increasing life expectancy of patients that suffer from orphan diseases,” said Aleksandr Voronovskiy, General Manager of Alexion in Russia.

“Pharmaceutical industry plays a unique role in addressing current healthcare challenges. Ferring actively develops innovative drugs to treat diseases in various therapeutic areas, and the medications that we produce are available on the pharmaceutical markets of 90 countries including Russia. We are happy to join AIPM and look forward to effective and long-term cooperation,” said Kirill Litovchenko, Managing Director of the Russian office of a Swiss pharmaceutical company Ferring Pharmaceuticals.

“With every new discovery and every medication that is developed we seek to improve the treatment of patients suffering from life threatening diseases around the globe. We are convinced that joined efforts of international pharmaceutical companies within the framework of key AIPM activities will contribute to this goal. Gilead Sciencesshares the fundamental principles of AIPM work and is ready for active participation in the activities of the Association,” said Igor Rukavishnikov, General Manager of Gilead Sciences in Russia.

Information:

Alexion Pharmaceuticals is a global biopharmaceutical company that specializes in developing and delivering life-transforming therapies for patients with severe and life-threatening orphan (ultra-rare) diseases. Alexion research and development programs are focused on hematology, nephrology, neurology and metabolic diseases. In 2012 and 2013 the company is ranked second in the Forbes Annual Ranking of the World's Most Innovative Companies.

Ferring Pharmaceuticals is a recognized leader in manufacturing original medications based on natural pituitary peptide hormones. The company develops innovative products in the field of gynecology and reproductive health, urology, oncology, gastroenterology and endocrinology. Ferring Pharmaceuticals is currently represented in more than 50 countries and employs approximately 4,500 people.

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company focuses on treatments for HIV/AIDS, liver diseases, serious respiratory and cardiovascular conditions. Gilead Sciences was founded in 1987 in Foster City, California. Today the company employs approximately 5,800 people across five continents.

The Association of International Pharmaceutical Manufacturers (AIPM) comprises more than 55 international pharmaceutical companies that provide over 80% of the world’s pharmaceutical products and over 60% of medicines imported into the Russian Federation.

For more information please contact:

Alexey Shavenzov, communication Director at AIPM

tel.: +7 (495) 933 7040, e-mail: a.shavenzov@aipm.org

Julia Oreshnikova, PR manager at AIPM

tel.: +7 (495) 933 70 40, mob.: +7 (903) 241 79 81, e-mail: j.oreshnikova@aipm.org

Tatiana Gavrilenko, AG-Loyalty

tel.: +7 (499) 788 91 57, mob.: +7 (926) 796 29 39, e-mail: tgav@ag-loyalty.com